Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus price objective of $7.83 for the company and are predicting that the company will post ($0.24) EPS for the current quarter, according to Zacks. Zacks has also given AzurRx BioPharma an industry rank of 98 out of 255 based on the ratings given to its competitors.
Separately, HC Wainwright set a $6.00 target price on shares of AzurRx BioPharma and gave the company a “buy” rating in a research report on Monday, July 2nd.
Shares of AzurRx BioPharma stock opened at $2.49 on Tuesday. AzurRx BioPharma has a 52-week low of $2.20 and a 52-week high of $5.25.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Recommended Story: Leveraged Buyout (LBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.